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Carbamazepine does not alter 
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ABSTRACT
Among the causes for sudden unexpected death (SUDEP) in epilepsy, the effects of 
antiepileptic drugs on the heart have been poorly explored. Based on this, the aim of our 
study was to evaluate the heart rate (in vivo and isolated ex vivo) and ventricular pressure 
(isolated ex vivo) of rats with and without epilepsy treated with carbamazepine. Four groups 
of adult, male Wistar rats (200-250 g) were studied: [A] control rats (n=8), received neither 
pilocarpine nor carbamazepine [B] carbamazepine-treated rats (n=8), received a daily dose 
of 120 mg/Kg, i.p. of carbamazepine for two weeks; [C] rats with epilepsy that received 
just saline solution (n=8); [D] rats with epilepsy that received a daily dose of 120 mg/
Kg, i.p. of carbamazepine for two weeks (n=8). Our results showed significant increase 
in heart rate in animals with epilepsy (with and without the use of carbamazepine) when 
compared to the control groups in vivo. In contrast, we did not find differences during 
isolated ex vivo experiments comparing animals with and without epilepsy and despite 
the use of carbamazepine. Our results suggest that, in isolation, carbamazepine may not 
be a potential risk factor for sudden unexpected death in epilepsy.
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Carbamazepina não altera o funcionamento cardíaco intrínseco em ratos com epilepsia
RESUMO
Entre as causas de morte súbita em epilepsia (SUDEPE), os efeitos das drogas 
antiepilépticas no coração têm sido pobremente explorados. Desta forma, o objetivo 
deste estudo foi avaliar a frequência cardíaca (in vivo e de forma isolada ex vivo) e a 
pressão ventricular (de forma isolada ex vivo) de ratos com e sem epilepsia tratados com 
carbamazepina. Quatro grupos de ratos Wistar machos adultos (peso 200 a 250 g) foram 
estudados: [A] ratos controle (n=8), não receberam pilocarpina ou carbamazepina; [B] ratos 
tratados com carbamazepina (n=8), receberam dose diária de carbamazepina de 120 mg/kg 
intraperitoneal, durante duas semanas (n=8); [C] ratos com epilepsia que receberam solução 
salina; [D] ratos com epilepsia que receberam dose diária de carbamazepina de 120 mg/
kg intraperitoneal durante duas semanas. Nossos resultados evidenciaram uma diferença 
estatisticamente significativa na média da freqüência cardíaca in vivo entre os animais 
com epilepsia (com e sem o uso de carbamazepina) quando comparados aos grupos 
controles in vivo. Em contraste, não observamos diferenças estatísticas nos experimentos 
ex vivo quando comparados os animais com ou sem epilepsia, a despeito do uso da 
carbamazepina. Nossos resultados sugerem que, de forma isolada, a carbamazepina pode 
não ser um fator de risco potencial para a ocorrência de morte súbita em epilepsia. 
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Epilepsy is the most common serious neurological 
condition1. Epidemiological studies suggest that between 
70 and 80% of people developing epilepsy will go into re-
mission, while the remaining patients continue to have 
seizures and are refractory to treatment with the current-
ly available therapies2,3. The most common risk factors for 
epilepsy are cerebrovascular diseases, brain tumors, alco-
hol abuse, traumatic head injuries, cortical developmental 
malformations, genetic inheritance and central nervous 
system infections4. In resource-poor countries, endemic 
infections, such as malaria and neurocysticercosis seem 
to be major risk factors5.
Sudden unexpected death in epilepsy (SUDEP) is de-
fined as sudden, unexpected, witnessed or unwitnessed, 
nontraumatic and nondrowning deaths in patients with 
epilepsy, with or without evidence of a seizure and ex-
cluding documented status epilepticus (SE), in which post 
mortem examination does not reveal a toxicological or 
anatomical cause of death6. Comparisons of estimates of 
incidence for SUDEP are difficult as different definitions 
of SUDEP have been used, not all patients have postmor-
tem examination, case ascertainment methods and source 
populations is varied7. The incidence of SUDEP has been 
estimated as 3.5/1000 person-years in a lamotrigine clini-
cal trial8, 0.5-1.4/1000 person-years in people with treated 
epilepsy9, 5.9/1000 person-years in outpatients with ep-
ilepsy at a tertiary referral centre10, 9/1000 person-years 
in candidates for epilepsy surgery and 0.35/1000 person-
years in a population-based study11. The National Gen-
eral Practice Study of Epilepsy (NGPSE), a community-
based study in the United Kingdom has seen the first case 
of SUDEP after 11,000 person-years of follow-up12 and 
the results of the Medical Research Council Antiepilep-
tic Drug Withdrawal Study showed that SUDEP among 
patients with epilepsy in remission is a rare event13. In-
formation concerning risk factors for SUDEP is conflict-
ing, but potential risk factors include: age11, early onset of 
epilepsy14, duration of epilepsy15, uncontrolled seizures, 
mainly in the temporal lobe epilepsy15,16, seizure frequen-
cy15-17 seizure type15-18, winter temperatures19 and antiepi-
leptic drugs therapy (AEDs)14,15,20. The impact of AEDs on 
the risk of SUDEP has been evaluated from different an-
gles: some studies have suggested more frequent AEDs 
changes or suboptimal AEDs dosage at the time of death 
in SUDEP patients14,18,21, however, some studies failed to 
confirm these findings or detect a difference in compli-
ance to AEDs therapy between SUDEP and non-SUDEP 
patients21-23. Moreover, the potential arrythmogenic side 
effect of carbamazepine has also been suspected to in-
crease the risk of SUDEP16,21,24, mainly when associated 
with plasma levels above 40 μmol/l21,23,24, but this issue 
also remains controversial14,15,21,23.
Considering the potential importance of carbam-
azepine (CBZ) on cardiovascular function that could cul-
minate in SUDEP, the aim of our study was to analyze the 
heart rate and the ventricular pressure in vivo and isolated 
ex vivo of rats with epilepsy and treated with CBZ.
METHOD
Animals
Four groups of adult, male Wistar rats (200-250 g) 
were studied: [A] control rats (n=8), received neither pilo-
carpine nor CBZ; [B] CBZ-treated rats (n=8), received 
just a dose of 40 mg/Kg three times day, i.p. of CBZ for 
two weeks; [C] rats with epilepsy that received just sa-
line solution (n=8); [D] rats with epilepsy that received 
a dose of 40 mg/Kg three times day, i.p. of CBZ for two 
weeks (n=8). It is important to note that the efficacy of 
CBZ dose (120 mg/kg) used in the present study was de-
termined in a previous study evaluated by our research 
group25. All animals used in our study were housed under 
standard controlled conditions (7:00 AM/7:00 P.M. light/
dark cycle; 20-22oC; 45-55% humidity) with food and wa-
ter ad libitum. All animals were treated according to pro-
tocols for animal care established by ethical committee 
from Federal University of São Paulo, and all efforts were 
made to minimize animal suffering. The project was ap-
proved by the local ethical committee.
Induction of status epilepticus (SE)
Adult male Wistar rats (250-300g) were given a sub-
cutaneous (s.c.) injection of methylscopolamine (1 mg/kg; 
Sigma, St. Louis, MO) followed 30 minutes later by an i.p. 
injection of pilocarpine hydrochloride (350 mg/kg; Sigma, 
St. Louis, MO) to induce SE. Seizure activity was moni-
tored considering animal behaviour and terminated with 
an i.p. injection of diazepam (10 mg/kg; Roche, Brazil) 
after 4 hr of convulsive SE. Only rats that displayed con-
tinuous, convulsive seizure activity for for 4 hr after pilo-
carpine treatment and without significant hypoxia were 
included in this study25. Sixty days after SE induction, all 
animals were fully recovered from status epilepticus and 
were selected for treatment with CBZ randomly. The rats 
treated with CBZ (Sigma, St. Louis, MO) started to re-
ceive a daily dose (120 mg/Kg, i.p.) during two weeks. 
Heart rate device 
To mesure the HR we used a HR apparatus devel-
oped in our laboratory, which allowed us to monitor heart 
electrical activity without inserting fixed skin electrodes 
(Fig 1)26. This characteristic is very important because any 
contact to the body of the animal can stress it and conse-
quently alter the HR27. In brief, the animals were placed 
inside the box, which was previously cleaned with a solu-
tion of 1 mM of acetic acid. The procedure with acid ace-
tic (followed by drying with paper towel) is fundamental 
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to eliminate coming scents of the previous animal. Fol-
lowing animal’s habituation (approximately 10 minutes) 
we started the commutation of the plus’s cables, with the 
objective to obtain a sign that makes possible the recog-
nition of the R-R interval of each animal. This procedure 
is very simple, taking approximately 15 minutes.
Isolated ex vivo procedures
Solutions – To wash the hearts, we used the Krebs-
Henseleit solution (KH) composed by (in mM): sodi-
um chloride 126.4; potassium chloride 4.6; KH2PO4 1.2; 
magnesium sulfate 1.2; sodium bicarbonate 13.6; calcium 
chloride 1.5; GLUCOSE 11.11, pH 7.4 to 36oC, saturated 
with 95% of O2, 5% of CO2. 
Experimental camera – The experimental camera 
used in our study was developed in our lab (Fig 2) and al-
lows the recording of the experiments in a well controlled 
way. The camera’s principles are: 
[A] The isolated heart is maintained under perfusion 
with physiologic solution in a retrograde way for the aor-
ta (Preparation of Langendorf );
[B]  The temperature of the solution is maintained 
(36oC); 
[C]  The solution is bubbled continuously with a car-
bonic solution (95% O2 + 5% CO2); 
[D] The pressure developed by the left ventricle dur-
ing the systole is monitored. 
Ventricular pressure and heart rate – As shown in 
Fig 3, a pressure transducer (TP) is coupled at a deriva-
tion of the bath that takes the perfusion solution to the 
heart in a close point to the stem. The pressure measured 
by the transducer during the contractions is amplified and 
registered in a digital oscilloscope (Tektronix, Inc, USA) 
with interface for printer. With this, we could character-
ize the mechanical activity of the hearts: the spontane-
ous heart frequency (Hz) and converted later for bpm, 
Fig 1. Heart rate apparatus: [1] acrylic box with electrodes; [2] switch of the electrodes; [3] amplifier; 
[4] scope.
Fig 2. Schematic figure of the experimental 
camera. To the center, we have the inferior and 
superior compartment, interlinked for a perfu-
sion hose [1] and a lateral hose [2], [3] peristaltic 
pump, [4] carbogenic solution, [5] and [6] hoses 
for carbogenic solution conduction and circula-
tion of the solution respectively, [7] stem for the 
aorta, [8] and [9] resistances, [10] power supply 
[11] pressure transducer.
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and the maximum pressure developed by the left ventri-
cle (mmHg).
Preparation of the sample and experimental pro-
tocol – All animals were killed with a guillotine 74 days 
after the pilocarpine injection. The hearts was removed 
and submerged in KH solution to clean its cameras, arter-
ies and veins. After this, the aorta was canulated and then 
mounted in the experimental camera. The heart was ret-
rograde perfused with KH (until to stabilize), that typically 
happened between 15 and 30 minutes. The registration ob-
tained in the oscilloscope was printed and analyzed later.
Statistical analysis 
To determine statistical differences between groups, 
we used a bifactorial variance analysis and the Turkey’s 
post-test. For each parameter (heart frequency and pres-
sure) we considered statistical differences among the 
groups with p<0.05.
RESULTS
Pilocarpine treatment sequentially induced the follow-
ing behavioral changes: akinesia, facial automatisms, and 
limbic seizures consisting of forelimb clonus with rear-
ing, salivation, and masticatory jaw movements and fall-
ing. This type of behavior built-up progressively into mo-
tor limbic seizures that recurred repeatedly and rapidly 
developed into SE. After SE, animals were comatose or 
unresponsive to their environment and akinetic. Behav-
ior returned to normal over a 3- to 5-day period. Sponta-
neous recurrent seizures in rats with epilepsy observed 
during the chronic period of the pilocarpine model of ep-
ilepsy were characterized by facial automatisms, forelimb 
clonus, rearing, loss of postural control and generalized 
clonic seizures lasting 40-60s. CBZ was introduced six 
day after pilocarpine injection and had a marked suppres-
sant action on spontaneous seizures. Seizure frequency 
during baseline period was 1.96 seizure episodes per day 
per animal, 0.097 during CBZ treatment period and 2.09 
during post-treatment period (p>0.05).
In the next step, the heart parameters (in vivo and 
isolated ex vivo procedures) were evaluated. Our results 
showed that HR in vivo (under influence of the autonom-
ic nervous system) of animals with epilepsy treated with 
CBZ (346±28 bpm) and without CBZ treatment (348±16 
bpm) were higher when compared with rats of the con-
trol groups (with CBZ: 307±20 bpm; and without CBZ: 
309±17 bpm; p>0.05) (Fig 3). On the other hand, in the 
isolated ex vivo experiments, no significant differences in 
mean HR of rats with epilepsy treated with CBZ (151±50 
bpm), without CBZ treatment (180±14 bpm) and con-
trol groups (with CBZ: 182±15 bpm; and without CBZ: 
177±16 bpm) were observed (Fig 4A). In the same way, a 
similar result was observed for the parameter of ventric-
ular pressure, i.e., rats with epilepsy and treated with CBZ 
(58±20 mmHg), without CBZ treatment (58±12 mmHg) 
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Fig 3. Means and standard deviation of the heart rates of all groups 
obtained in vivo situation.
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Fig 4. Means and standard deviation of the heart rates and ventric-
ular pressures of all groups obtained in vitro situation.
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and control groups (with CBZ: 54±5 mmHg; and with-
out CBZ: 56±10 mmHg) did not show statistical differ-
ences (Fig 4B). 
DISCUSSION
The present study evaluated the heart rate (in vivo 
and isolated ex vivo) and ventricular pressure (isolated ex 
vivo) of rats with and without epilepsy treated with CBZ. 
Our results showed that rats with epilepsy had a signifi-
cant increase in HR when compared to controls, probable 
secondary to functional autonomic changes that occur in 
cerebral function28. Although, CBZ did not increase in a 
maintained way significantly the HR of rats studied dur-
ing in vivo situation and did not alter the ventricular pres-
sure during isolated ex vivo situation as well.
As we know, SUDEP is responsible for 7.5% to 17% of 
all deaths in epilepsy and has an incidence among adults 
between 1:500 and 1:1,0005,21, and AEDs therapy is one 
of the many risk factors suggested for SUDEP. Although 
several studies suggested increase risk of SUDEP with in-
creasing number of AEDs used7,29, a very few studies have 
made attempts to verify if there is an association between 
specific AEDs, cardiovascular abnormalities and hence 
SUDEP. Furthermore, it has been shown that CBZ is able 
to affect the conduction system of the heart and the au-
tonomic nervous system as well29-31. Although our study 
did not find HR and ventricular pressure differences with 
CBZ administration during in vivo and isolated ex vivo 
situation, a number of arguments might be put forward. 
To do so, interesting studies developed by Timmings32,33 
showed that CBZ was disproportionately represented in 
patients suffering SUDEP. Thus, the authors demonstrat-
ed that 11 of the 14 SUDEP (79%) patients were taking 
CBZ at the time of death. Moreover, the results also in-
dicated that one patient was not taking any drug thera-
py, and died during his first seizure, reducing the num-
ber of evaluable ‘drug usage’ patients to 13, and increasing 
the proportion taking CBZ at the time of death to 85%. 
As possible mechanisms, Timmings33 suggests that CBZ 
induced lengthening of the ECG Q-T interval combined 
with a mild pro-arrhythmic effect of epileptic seizure dis-
charges, and consequent transient cardiac instability lead-
ing to arrhythmic death32,33. It is important to note that in 
these studies, no attempts were made to control and asso-
ciate SUDEP cases for other recognized potential SUDEP 
risk factors, such as duration of epilepsy, seizure frequen-
cy, age, polytherapy and winter temperatures7,19,34. In par-
allel, Nilsson and colleagues15 demonstrated that high 
CBZ plasma levels (above 40 μmol/l) was a risk factor for 
SUDEP, point to the risks associated with unstable severe 
epilepsy. Although this result was not confirmed in the 
U.S. study15, we have to be in mind that CBZ is metabo-
lized by hepatic P450 isoenzyme CYP 3A and when drugs 
that inhibit CYP 3A are administered together, plasma 
levels of parent drug may increase, thus leading to further 
cardiovascular abnormalities (lengthening of the QT in-
terval) and increasing the risk of sudden death35.
In contrast to CBZ as potential risk factor to SUDEP, 
there is a growing body of clinical studies in agreement 
with our experimental results suggesting that CBZ, at 
therapeutic levels, has no or minimal effects on the heart 
conduction system, supporting its safe use in the absence 
of cardiac disease1,31. In fact, three larger controlled stud-
ies described that the use of CBZ was not increased in 
SUDEP cases when compared with control subjects14,15,18. 
Following this, it is reasonable to think that CBZ may not 
precipitate prolongation of the QT interval into SUDEP, 
but patients are still at risk for cardiovascular alterations 
for other reasons such as co-medication with other drugs, 
electrolyte imbalance and hepatic or renal impairment. 
SUDEP is usually unwitnessed and the majority of 
people dying with SUDEP are found in or near the bed18, 
presumably during sleep. Quite interesting, Hennessy 
and colleagues36 described that abrupt withdrawal of 
CBZ leads to enhanced sympathetic activity in sleep as 
evidenced by changes in heart hate variability, suggest-
ing that increased sympathetic activity in the setting of 
seizure-induced hypoxia could predispose to SUDEP. Al-
though our study has only considered the heart rate pa-
rameters during CBZ treatment and we did not find any 
cardiovascular dysfunctions in our set of experiments, 
this question should not be neglected. As we know, hy-
ponatremia is a usual electrolyte disorder and is defined 
as serum sodium <135 mmol per liter3. Because of the 
fact that sodium is the dominant electrolyte of the extra-
cellular fluid and the primary determinant of serum os-
molality, the disturbances of sodium homeostasis can lead 
to pathologic alterations in cell functions37,38. It has been 
determined that diuretics are the most common drugs 
which induce hyponatremia, but there are a few case re-
ports in literature in which hyponatremia is induced by 
another therapy, including CBZ treatment39. Taken to-
gether, this electrolytic anomaly can derive in secondary 
cardiovascular effects, in so outstanding occasions, as to 
produce the phenomenon denominated SUDEP.
According to the current knowledge, improved sei-
zure control seems to be one of the most important mea-
sures to prevent SUDEP; however, AEDs (mainly poly-
therapy management) are equally dangerous regarding 
SUDEP31. Finally, further studies are needed to gain a bet-
ter understanding of the role of CBZ as a potential risk 
factor to SUDEP, but in the mean time caution with CBZ 
continuous to be prudent and necessary.
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